Shares of GeneDx Holdings Corp. (NASDAQ:WGS – Get Free Report) have received a consensus rating of “Moderate Buy” from the six research firms that are currently covering the firm, MarketBeat reports. Three equities research analysts have rated the stock with a hold recommendation and three have issued a buy recommendation on the company. The average 1-year price objective among brokerages that have updated their coverage on the stock in the last year is $41.67.
WGS has been the subject of a number of research analyst reports. Wells Fargo & Company initiated coverage on shares of GeneDx in a research note on Tuesday, August 27th. They issued an “equal weight” rating and a $34.00 target price for the company. The Goldman Sachs Group upped their target price on shares of GeneDx from $32.00 to $54.00 and gave the stock a “neutral” rating in a research note on Wednesday, October 16th. Craig Hallum upped their target price on shares of GeneDx from $43.00 to $46.00 and gave the stock a “buy” rating in a research note on Wednesday, July 31st. TD Cowen upped their target price on shares of GeneDx from $46.00 to $50.00 and gave the stock a “buy” rating in a research note on Wednesday, July 31st. Finally, BTIG Research upped their target price on shares of GeneDx from $35.00 to $45.00 and gave the stock a “buy” rating in a research note on Wednesday, July 31st.
Check Out Our Latest Analysis on WGS
Insider Transactions at GeneDx
Institutional Inflows and Outflows
Large investors have recently bought and sold shares of the stock. Renaissance Technologies LLC bought a new position in GeneDx in the 2nd quarter valued at about $2,362,000. Millennium Management LLC increased its holdings in shares of GeneDx by 193.5% during the second quarter. Millennium Management LLC now owns 311,401 shares of the company’s stock worth $8,140,000 after purchasing an additional 205,318 shares during the period. Algert Global LLC bought a new position in shares of GeneDx during the second quarter worth approximately $356,000. Calamos Advisors LLC bought a new position in shares of GeneDx during the second quarter worth approximately $1,137,000. Finally, Point72 Asset Management L.P. increased its holdings in shares of GeneDx by 227.4% during the second quarter. Point72 Asset Management L.P. now owns 156,745 shares of the company’s stock worth $4,097,000 after purchasing an additional 108,864 shares during the period. 61.72% of the stock is owned by institutional investors.
GeneDx Price Performance
WGS opened at $60.05 on Wednesday. The company has a quick ratio of 2.22, a current ratio of 2.38 and a debt-to-equity ratio of 0.27. GeneDx has a 12 month low of $1.16 and a 12 month high of $61.96. The company has a fifty day simple moving average of $40.84 and a 200 day simple moving average of $29.54. The stock has a market cap of $1.57 billion, a P/E ratio of -11.59 and a beta of 2.32.
GeneDx (NASDAQ:WGS – Get Free Report) last released its quarterly earnings data on Tuesday, July 30th. The company reported ($0.11) EPS for the quarter, beating analysts’ consensus estimates of ($0.26) by $0.15. GeneDx had a negative net margin of 48.21% and a negative return on equity of 22.71%. The business had revenue of $70.51 million during the quarter, compared to analysts’ expectations of $58.90 million. On average, research analysts expect that GeneDx will post -0.75 EPS for the current year.
About GeneDx
GeneDx Holdings Corp., through its subsidiaries, provides genomics-related diagnostic and information services. The company offers Centrellis, an AI-driven health intelligence platform that integrates digital tools and artificial intelligence allowing scientists to ingest and synthesize clinical and genomic data to deliver comprehensive health insights.
Read More
- Five stocks we like better than GeneDx
- Election Stocks: How Elections Affect the Stock Market
- Is Spotify Stock Poised to Soar? Options Traders Think So
- How to Know Which Cryptocurrency to Buy: A Guide for Investors
- Misses and Beats: 3 Stocks That Are Moving Markets Right Now
- Golden Cross Stocks: Pattern, Examples and Charts
- Cisco on the Rise: AI Potential and Analyst Upgrades Drive Gains
Receive News & Ratings for GeneDx Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GeneDx and related companies with MarketBeat.com's FREE daily email newsletter.